2012年　放射線生命科学講座　研究発表

 

河野和、藤原志保、和田奈緒子、井崎幹子、幸宏道、奥野豊、猪山賢一、山崎浩、坂井晃*、満屋裕明、畑裕之：骨髄腫細胞におけるCD138発現の低下．第37回日本骨髄腫学会学術集会、京都市、2012.7.7.（日本骨髄腫学会誌 2(1)：12、2012.7）
Yawara Kawano, Shiho Fujiwara, Naoko Wada, Mikiko Izaki, Hiromichi Yuki, Yutaka Okuno, Kenichi Iyama, Hiroshi Yamasaki, Akira Sakai*, Hiroaki Mitsuya, Hiroyuki Hata：CD138-low MM cells are of immature phenotype and low sensitivity to lenalidomide. The 10th Annual Meeting of Japanese Society of Medical Oncology, Kyoto, 2012.7.7 (International Journal of Myeloma 2(1):12, 2012.7)

 

黒田芳明、美山貴彦、兵頭英出夫、坂井晃*：VCD(Vel・CPA・DEXA)療法の使用経験．第37回日本骨髄腫学会学術集会、京都市、2012.7.8. （日本骨髄腫学会誌 2(1)：26、2012.7）

Yoshiaki Kuroda, Takahiko Miyama, Hideo Hyodo, Akira Sakai*：Treatment of multiple myeloma and AL amyloidosis with bortezomib, cyclophosphamide, and dexamethasone. The 10th Annual Meeting of Japanese Society of Medical Oncology, Kyoto, 2012.7.7 (International Journal of Myeloma 2(1):26, 2012.7) 

 

Yawara Kawano, Shiho Fujiwara, Naoko Wada, Mikihiko Izaki, Hiromichi Yuki, Yutaka Okuno, Kenichi Iyama, Hiroshi Yamasaki, Akira Sakai*, Hiroaki Mitsuya, Hiroyuki Hata :CD138-low MM cells are of immature phenotype and reduced lenalidomide(LEN) sensitivity.　The 74th Annual Meeting of Japanese Society of Hematology, Kyoto, 2012.10.19 (The Japanese Journal of Clinical Hematology  53(9):446, 2012.9)

 

坂井晃 *：多発性骨髄腫の合併症とそのマネージメント―骨病変・腎障害・末梢神経障害― …. 第74回日本血液学会学術集会 、京都市、2012.10.20. (臨床血液 53(9):876, 2012.9)
Akira Sakai*:Complications and their management in multiple myeloma.-bone disease, renal impairment, peripheral neuropathy-The 74th Annual Meeting of Japanese Society of Hematology, Kyoto, 2012.10.20 (The Japanese Journal of Clinical Hematology 53(9):876, 2012.9)

 

Shinsuke Iida, Kiyoshi Ando, Kensi Suzuki, Akira Sakai*, Michinori Ogura, Kensei Tobinai, Morio Matsumoto, Kosei Matsue, Yasuhito Terui, Kazuteru Ohashi, Takaaki Chou, Kazutaka Sunami, Atsushi Shinagawa, Nobuyuki Aotsuka, Hirohiko Shibayama, Takayuki Takahashi, Masami Ishii, Tomomitsu Hotta : : A phase I/II study of VMP as initial treatment for multiple myeloma in Japan. The 74th Annual Meeting of Japanese Society of Hematology, Kyoto, 2012.10.20(The Japanese Journal of Clinical Hematology 53(9):312, 2012.9)

 

Yoshiaki Kuroda, Hideo Hyodo, Koji Arihiro, Akira Sakai *: Clinical features of Castleman disease and treatment with tocilizumab . The 74th Annual Meeting of Japanese Society of Hematology, Kyoto, 2012.10.20(The Japanese Journal of Clinical Hematology 53(9):313, 2012.9)

 

Keichiro Mihara, Akira Sakai*, Yoshihiro Takihara, Akiko Kimura: Evaluation of B-lymphoma cells involved in bone marrow: usefulness of CD19-gating flow cytometry .  The 74th Annual Meeting of Japanese Society of Hematology, Kyoto, 2012.10.20(The Japanese Journal of Clinical Hematology 53(9):356, 2012.9)

 

Takasu M., Higaki T., Tani C., Kiguchi M., Tatsugami F., Awai K., Kuroda Y.,Sakai A*. Patients with Multiple Myeloma: Finite Element Analysis Using Multidetector CT to Predict Pathological Fracture.  Program in Brief, Radiological Society of North America 98th Scientific Assembly and Annual Meeting. p351, 2012.

 

Takasu M., Kaichi Y., Tanitame K., Date S., Akiyama Y., Awai K., Kuroda Y., Sakai A*: MR Evaluation of Multiple Myeloma at 3.0 T: How Does Protocol Selection Affect Lesion Conspicuity? Program in Brief, Radiological Society of North America 98th Scientific Assembly and Annual Meeting. p351, 2012.

 

三原圭一朗，坂井晃*，瀧原義宏，木村昭郎：B細胞性リンパ腫の骨髄浸潤の評価～CD19 gating フローサイトメトリー法の有用性～．
第52回日本リンパ網内系学会総会，福島県福島市，2012.6.16.（日本リンパ網内系学会会誌　52（第52回日本リンパ網内系学会・予稿集)：29，2012.5.

 

大津留晶，安村誠司，鈴木眞一，細谷光亮，藤森敬也，坂井晃*，神谷研二*，阿部正文，山下俊一：放射線災害医療と県民健康管理調査～原爆・チェルノブイリの教訓から～シンポジウムＳ７緊急被ばく医療．第55回日本放射線学会，宮城県仙台市，2012.9.6.

 

大津留晶，安村誠司，鈴木眞一，細谷光亮，藤森敬也，坂井晃*，神谷研二*，阿部正文，山下俊一：福島の現況と県民健康管理調査を通じた長期的な健康管理「低線量(率)被ばくの生体影響を考える」～科学的事実に基づく情報発信のために～．日本放射線影響学会ワークショップ，福島県郡山市，2012.10.30-31.